For instance, post-neoadjuvant T-DM1 has recently demonstrated improved DFS and OS in HER2+ BC patients failing to achieve pCR during pre-operative trastuzumab-based biochemotherapy [101], while post-neoadjuvant capecitabine has proven to be effective in increasing DFS and OS in TNBC patients failing to achieve tumor pCR after neoadjuvant therapy [102]. This evidence concerns the gene ERBB2 and breast cancer.